Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10195792 | 0.86 | DPP4 (0.35) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL3705644 | 0.85 | DPP4 (0.44) | DPP4PIN1MMEMMEL1CYP3A4 | |
| SCHEMBL8290320 | 0.84 | CTSS (0.41) | DPP4PIN1DPP8DPP9DPP7 | |
| SCHEMBL25075296 | 0.83 | DPP4 (0.40) | DPP4PIN1DPP8DPP9DPP7 | |
| SCHEMBL15103376 | 0.83 | DPP4 (0.40) | DPP4PIN1DPP8DPP9DPP7 | |
| SCHEMBL15108795 | 0.83 | DPP4 (0.40) | DPP4PIN1DPP8DPP9DPP7 | |
| SCHEMBL699083 | 0.82 | DPP4 (0.39) | DPP4PIN1DPP8DPP9DPP7 | |
| SCHEMBL699084 | 0.82 | DPP4 (0.39) | DPP4PIN1DPP8DPP9DPP7 | |
| SCHEMBL342707 | 0.81 | DPP4 (0.43) | DPP4PIN1 | |
| SCHEMBL342708 | 0.81 | DPP4 (0.43) | DPP4PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-08-30 | — | — | US | disclosed |
| US-20120065209-A1 | TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE DERIVATIVES SALTS, PREPARATION METHODS AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-03-15 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015146-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP3 | DPP4 1/4885PIN1 353/4885DPP8 5/4885 |
| US-20120220766-A1 | TETRAHYDRO-IMIDAZO[1,5-alpha] PYRAZINE DERIVATIVES, PREPERATION PROCESS AND MEDICINAL USE THEREOF | DPP4, DPP3, DPP7 | DPP4 1/4885PIN1 146/4885DPP8 6/4885 |
| US-20120065209-A1 | TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE DERIVATIVES SALTS, PREPARATION METHODS AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | DPP4 1/4885PIN1 238/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.